ConTIP’s ProVate is a ready-to-use device developed for vaginal insertion. Credit: Chinnapong / Shutterstock.com.

Indegene has unveiled plans to expand its partnership with ConTIPI Medical to bring the ProVate device to assist women experiencing pelvic organ prolapse (POP).

Developed by ConTIPI, ProVate is a ready-to-use device designed for vaginal insertion by the user. The device comes with a simple applicator, resembling a menstrual tampon, therefore enabling women to take charge of their own treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ConTIPI has already received a 510(k) clearance from the US Food and Drug Administration for this device to commercialise in the US. The device also has a CE mark to market in Europe.

ConTIPI Medical CEO and medical director Dr Elan Ziv said: “We have worked with Indegene to help us navigate the complex process from product innovation to patient adoption and we are excited to continue to partner throughout this commercialisation journey.”

The expanded partnership scope encompasses various services throughout the commercialisation process.

Indegene will provide services comprising pricing, reimbursement and market access, pharmacovigilance, medical communications, sales, regulatory, marketing and commercial operations support.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The two companies will work towards enhancing revenue and ensuring a predictable cash outflow.

ConTIPI will leverage Indegene’s data-driven omnichannel marketing solution to deliver a significant impact compared to field sales representatives alone.

Indegene uses its own artificial intelligence technology and health care provider (HCP) data to precisely categorise and focus on HCPs.

These capabilities assist clients in implementing optimised sales and marketing strategies.

Indegene emerging biotech and key accounts senior vice-president Timothy Moore said: “With this joint commercialisation agreement, we will continue to offer ConTIPI the exceptional strategic advantage and services that industry leaders have come to trust from Indegene.”